TriState Capital Declares Quarterly Dividend on Perpetual Preferred Stock
Get Alerts TSC Hot Sheet
Join SI Premium – FREE
PITTSBURGH--(BUSINESS WIRE)-- The Board of Directors of TriState Capital Holdings, Inc. (Nasdaq: TSC) declared a quarterly cash dividend on the company’s Series A Non-Cumulative Perpetual Preferred Stock (Nasdaq: TSCAP) of $0.421875 per depositary share. The preferred stock dividend is payable on April 1, 2019 to holders of record as of March 18, 2019.
ABOUT TRISTATE CAPITAL
TriState Capital Holdings, Inc. (Nasdaq: TSC) is a bank holding company headquartered in Pittsburgh, Pa., providing commercial banking, private banking and investment management services to middle-market companies, institutional clients and high-net-worth individuals. Its TriState Capital Bank subsidiary had $5.9 billion in assets, as of December 31, 2018, and serves middle-market commercial customers through regional representative offices in Pittsburgh, Philadelphia, Cleveland, Edison, N.J., and New York City, as well as high-net-worth individuals nationwide through its national referral network of financial intermediaries. Its Chartwell Investment Partners subsidiary had $9.2 billion in assets under management, as of December 31, 2018, and serves as the advisor to The Berwyn Funds and Chartwell Mutual Funds. For more information, please visit http://investors.tristatecapitalbank.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190131005009/en/
MEDIA CONTACT
Jack Horner
Hornercom
267-932-8760,
ext. 302
412-600-2295 (mobile)
[email protected]
INVESTOR CONTACTS
Jeff Schoenborn and Kate Croft
Casteel
Schoenborn
888-609-8351
[email protected]
Source: TriState Capital Holdings, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trustovi Announces Availability of Its Estate Planning Platform Pairing a Technology-Supported Client Process With Attorney-Prepared Plans
- Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma
- Best Crypto to Buy in October 2026? Swiss Retail Bitcoin ETF Approval Meets Remittix Earn’s Upcoming Launch With Up to 22% APY
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share